Furthermore, the survival differences adjusted by the clinical stage indicated that CHRM1–5 and EGFR expression levels were significant (p < 0.01) in stage 3, and also significant (p < 0.001) in stage 4 in STAD patients. Here, EGFR is linked to gastric adenocarcinoma.